Pharmaceutical company Pharmstandard plans to maintain net profit dynamics in 2012 at the same level as last year, chief financial officer Yelena Arkhangelskaya said, Interfax reported.
The company's net profit climbed 23 percent to 8.8 billion rubles ($280 million) in 2011. In the first half of 2012, it fell 27 percent to 3 billion rubles.
The company is hoping to see profits climb in the second half, which is usually when it sees its maximum demand for medicines, Arkhangelskaya said.
Capital investment in the first half totaled 566 million rubles, and the company plans to spend another 1 billion rubles in the second half, she said. Capital investment in 2011 was 1.75 billion rubles.
Pharmstandard CEO Igor Krylov said pharmaceuticals production would develop through acquisitions.
"We are becoming more aggressive with investments. Growth will be ensured through acquisitions," he said.
(MT)
Related articles:
A Message from The Moscow Times:
Dear readers,
We are facing unprecedented challenges. Russia's Prosecutor General's Office has designated The Moscow Times as an "undesirable" organization, criminalizing our work and putting our staff at risk of prosecution. This follows our earlier unjust labeling as a "foreign agent."
These actions are direct attempts to silence independent journalism in Russia. The authorities claim our work "discredits the decisions of the Russian leadership." We see things differently: we strive to provide accurate, unbiased reporting on Russia.
We, the journalists of The Moscow Times, refuse to be silenced. But to continue our work, we need your help.
Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and every contribution makes a significant impact.
By supporting The Moscow Times, you're defending open, independent journalism in the face of repression. Thank you for standing with us.
Remind me later.